Kite Pharma, Inc. Deferred Tax Assets, Net of Valuation Allowance
Kite Pharma, Inc. had Deferred Tax Assets, Net of Valuation Allowance of $18.58 million as of 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2017-02-28
- 2016-12-31: Deferred Tax Assets, Net of Valuation Allowance $18.58M.
- 2015-12-31: Deferred Tax Assets, Net of Valuation Allowance $4.94M.
- 2014-12-31: Deferred Tax Assets, Net of Valuation Allowance $1.44M.
- 2013-12-31: Deferred Tax Assets, Net of Valuation Allowance $419.00K.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2016-12-31 | $18.58M 10-K · filed 2017-02-28 |
| 2015-12-31 | $4.94M 10-K · filed 2017-02-28 |
| 2014-12-31 | $1.44M 10-K · filed 2015-03-26 |
| 2013-12-31 | $419.00K 10-K · filed 2015-03-26 |